(Q36369836)

13 August 2017

title

Use of genomic signatures in therapeutics development in oncology and other diseases (English)

1 reference

13 August 2017

Simon R

1

1 reference

13 August 2017

Wang SJ

series ordinal

2

1 reference

13 August 2017

publication date

1 May 2006

1 reference

The Pharmacogenomics Journal

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

166-173

1 reference

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Creating incentives for genomic research to improve targeting of therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Sample size for gene expression microarray experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Clinical trial design for microarray predictive marker discovery and assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Use of unlinked genetic markers to detect population stratification in association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

Evaluating the efficiency of targeted designs for randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

inferred from DOI database lookup

7 January 2021

based on heuristic

Case-control association studies in pharmacogenetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500349

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.TPJ.6500349

1 reference

13 August 2017

1 reference